πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 132 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10040858

Anti-CSF1R antibodies for treating PVNS

Five Prime Therapeutics, Inc. Β· Granted Tue Aug 07 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 02 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10023627

Vascular endothelial growth factor fusion protein

KOREA PRIME PHARM CO., LTD. Β· Granted Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10016484

Methods of treating lung cancer

Five Prime Therapeutics, Inc. Β· Granted Tue Jul 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9957327

Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

Five Prime Therapeutics, Inc. Β· Granted Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9849167

Compositions and methods for combination therapy with dengue virus and dendritic cells

PrimeVax Immuno-Oncology Β· Granted Tue Dec 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9775881

Methods of treating mesothelioma by administration of compounds comprising FGFR1 ECD

Five Prime Therapeutics, Inc. Β· Granted Tue Oct 03 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9765147

Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. Β· Granted Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9730989

Compositions and methods for combination therapy with dengue virus and dendritic cells

PrimeVax Immuno-Oncology Β· Granted Tue Aug 15 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9713637

Bacillus anthracis HtrA-defective-derived vaccines

State of Israel, Prime Minister's Office, Israel Insitute For Biological Research Β· Granted Tue Jul 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9695243

Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

Five Prime Therapeutics, Inc. Β· Granted Tue Jul 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 29 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9657267

Ex host maturation of germline stem cells

PrimeGen Biotech LLC Β· Granted Tue May 23 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 18 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9475871

Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins

Five Prime Therapeutics, Inc. Β· Granted Tue Oct 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9200075

Nucleic acids encoding antibodies that bind colony stimulating factor 1 receptor (CSF1R)

Five Prime Therapeutics, Inc. Β· Granted Tue Dec 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9192683

Methods of treating disease with FGFR1 fusion proteins

Five Prime Therapeutics, Inc. Β· Granted Tue Nov 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9173957

FGFR2 fusion proteins comprising C-terminal deletion mutants of FGFR2-IIIC

Five Prime Therapeutics, Inc. Β· Granted Tue Nov 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9175065

FGFR extracellular domain acidic region muteins

Five Prime Therapeutics, Inc. Β· Granted Tue Nov 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9169313

Method of treatment of cancers characterized by ligand-dependent activating mutations in F

Five Prime Therapeutics, Inc. Β· Granted Tue Oct 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8951972

FGFR1 extracellular domain combination therapies for lung cancer

Five Prime Therapeutics, Inc. Β· Granted Tue Feb 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8920800

Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins

Five Prime Therapeutics, Inc. Β· Granted Tue Dec 30 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8901277

Interferon alpha mutant and its polyethylene glycol derivative

Beijing Tri-Prime Genetic Engineering Co., Ltd Β· Granted Tue Dec 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8871907

Glycosylated immunoglobulin and immunoadhesin comprising the same

KOREA PRIME PHARM CO., LTD. Β· Granted Tue Oct 28 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8747845

Methods of treatment by administering antibodies that bind colony stimulating factor 1 rec

Five Prime Therapeutics, Inc. Β· Granted Tue Jun 10 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 05 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8685931

Hair growth methods using FGFR3 extracellular domains

Five Prime Therapeutics, Inc. Β· Granted Tue Apr 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8673375

Herbal extract products and methods

Prime Interaction Holdings Limited Β· Granted Tue Mar 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted